Many trials in the last decade that have led to FDA drug approvals didn't report on race and the ones that did were lacking in racial diversity.
The CLARITY trial looked at measurable residual disease negativity in 54 patients with relapsed or refractory chronic lymphocytic leukemia who received ibrutinib in combination with venetoclax.
Laparoscopic treatment during pregnancy is becoming an option for more women.
There are continued advances in the use of biomarkers to guide drug development and the more targeted delivery of medicine.
A new meta-analysis compared survival in patients with advanced non–small cell lung cancer who received immunotherapy vs those who received chemotherapy.
Despite the toll chemotherapy can take on the body, experts say it's possible for athletes to exercise while undergoing treatment for cancer.
Among 598 trials published between 2003 and 2018, only 107 had a female corresponding author, though women made up anywhere from 27% to 39% of academic oncologists during this time period.
The new recommendations will help standardize neoadjuvant clinical trial methodology and develop a path for regulatory review and approval of neoadjuvant therapies in melanoma.
Negative trial findings suggest immune checkpoint inhibitors may not be the best type of immunotherapy to treat pancreatic cancer.
The United States Preventive Services Task Force issued a statement reaffirming its 2004 recommendation against screening for pancreatic cancer in asymptomatic adults.